The third phase of clinical trials of Covaxin began at the Infectious Disease (Fever Hospital) Hospital at Gorantla on Wednesday. District Collector I. Samuel Ananda Kumar launched the vaccine trials. The vaccine vials have come from the Indian Council for Medical Research, Pune.
The Collector said that based on the guidelines of ICMR, the phase-3 trials have begun at the ID Hospital. The phase-2 clinical trials were held at Nizam’s Institute of Medical Sciences, Hyderabad in which 717 patients were covered.
The ICMR trials at ID Hospital would cover 1,000 patients in a month and the detailed report would be sent to ICMR. Those willing to undergo trials would have to give their written consent. Based on the clinical trials, the vaccine might be launched in 2021.
Principal of Guntur Medical College, C. Padmavathy Devi, said that it was due to the persistent efforts of the Collector that the spread of COVID-19 was prevented.
Joint Collector (WS and VS) P. Prasanthi, Superintendent of ID Hospital Raghu, Deputy Superintendent, GGH, Nageswaramma were present.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Support Quality Journalism.
*Our Digital Subscription plans do not currently include the e-paper, crossword and print.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath
Please Email the Editor